

STUDIES ON SF-1902 A₂~A₅, MINOR COMPONENTS
OF SF-1902 (GLOBOMYCIN)

SHOJI OMOTO, HIROKO OGINO and SHIGEHARU INOUE

Central Research Laboratories, Meiji Seika Kaisha, Ltd.,
Morooka-cho, Kohoku-ku, Yokohama 222, Japan

(Received for publication June 6, 1981)

Four members of globomycin, SF-1902 A₂, A₃, A_{4a} and A_{4b} were newly isolated from the culture of *Streptomyces hygroscopicus* SF-1902. These minor components shared four amino acids in common and the fifth was either valine or *allo*-isoleucine. The fatty acid moiety varied from 3-hydroxy-2-methylheptanoic acid in A₂ to 3-hydroxy-2-methylundecanoic acids in A_{4b}. The length of alkyl chain greatly affected the antibacterial activity, and maximum activity was shown by the homologue (A₅) possessing the longest alkyl chain.


In our screening of new antibiotics, a novel neutral antibiotic complex, SF-1902 A group was isolated from the culture of *Streptomyces hygroscopicus* SF-1902. The complex contained about ten components in which A₁* identical with globomycin¹⁾ was dominant. From the minor components so far five, A₂, A₃, A_{4a}, A_{4b} and A₅ were characterized in this laboratory. Isolation and structure of SF-1902 A₅ were reported previously²⁾. In this paper, we wish to describe isolation and structures of SF-1902 A₂, A₃, A_{4a} and A_{4b} as well as structure-activity relationship among them. Characterization of the producing organism and its fermentation have already been reported³⁾.

Isolation and Purification of Minor Components

The SF-1902 complex was a neutral and solvent soluble material, which could be extracted with ethyl acetate from the fermentation broth and with acetone from the mycelia. SF-1902 A_{4a}, A_{4b} and A₅ (A_{4a}, A_{4b} and A₅) were minute in broth filtrates but substantial amounts (~8%) of these components were found in the organic extract from mycelia.

Isolation of SF-1902 complex was effected by repeated chromatography over silica gel followed by crystallization from aqueous acetonitrile. A crystalline complex thus obtained contained 70% of globomycin (SF-1902 A₁). The minor components were relatively concentrated in the mother liquor, as

Fig. 1. Structures of SF-1902 components.



Component	R	n
A ₂	CH ₃ CH ₂	3
A ₃	CH ₃	5
A ₁ =globomycin	CH ₃ CH ₂	5
A _{4a}	CH ₃ CH ₂	6
A _{4b}	CH ₃	7
A ₅	CH ₃ CH ₂	7

* Formerly designated SF-1902.²⁾

Chart 1. Isolation and purification of SF-1902 minor components.




Table 1. Physico-chemical properties of SF-1902 components.

	A ₂	A ₃	A ₁ = globomycin	A _{4a}	A _{4b}	A ₅
Appearance	Colorless needles					
M.p. (°C)	114~117	115~118	115~117	114~117	115~118	113~117
UV	End absorption					
[α] _D ²⁵ (c 1, CHCl ₃) ^{a)}	-16°	-16°	-17°	-16°	-16°	-16°
Microanalysis Found: (%)	C, 57.35 H, 8.49 N, 11.01	C, 58.21 H, 8.60 N, 10.78	C, 58.45 H, 8.67 N, 10.51	C, 59.00 H, 8.74 N, 10.26	C, 59.28 H, 8.75 N, 10.35	C, 59.68 H, 8.87 N, 10.12
Molecular formula	C ₃₀ H ₅₅ N ₅ O ₉	C ₃₁ H ₅₅ N ₅ O ₉	C ₃₂ H ₅₇ N ₅ O ₉	C ₃₃ H ₅₉ N ₅ O ₉	C ₃₃ H ₅₉ N ₅ O ₉	C ₃₄ H ₆₁ N ₅ O ₉
Molecular weight	627	641	655	669	669	683
HPLC ^{b)} (minutes)	6.3	7.5	9.0	11.2	11.7	14.8
TLC ^{c)} (Rf value)	0.45					
Color reaction	Positive: Sulfuric acid, LEMIEUX, I ₂ , GREIG-LEABACK Negative: SAKAGUCHI, ninhydrin					

a) After vacuum drying at 60°C; b) Develosil ODS (4.6 mm × 250 mm), CH₃CN - H₂O, 70: 30 (0.7 ml/minute, 15 kg/cm²); c) Silica gel 60 (E. Merck), CHCl₃ - MeOH, 5: 1

shown in Chart 1. The crystalline complex seemed to be homogeneous on TLC or normal phase HPLC, but was clearly resolved into multiple peaks in reversed-phase HPLC on ODS-silica gel.

Physico-chemical Properties of Four Minors

Physico-chemical properties of four minor components are listed in Table 1. They showed properties similar to globomycin, but differed from it in the molecular weight by 14 or its multiple. As a representative, SF-1902 A₈ (A₃) was selected, and its IR and PMR spectra are shown in Figs. 2 and 3. CMR chemical shifts of four minors as well as globomycin and A₅ are shown in Table 2. Assignments

Fig. 2. IR Spectrum of SF-1902 A₈ (KBr).




Fig. 3. PMR Spectrum of SF-1902 A₈ (200 MHz, CDCl₃).




Table 2. ^{13}C Chemical shifts of SF-1902 minor components (ppm).

		A ₂	A ₃	A ₁ = globomycin	A _{4a}	A _{4b}	A ₅
<i>N</i> -Me-Leu	C _α	68.1	68.2	68.8	68.4	68.1	68.5
	C _β	38.2	38.4	38.4	38.3	38.2	38.3
	C _γ	24.1	24.1	24.1	24.2	24.2	24.2
	C _{δ1}	23.1	23.1	23.0	23.0	23.1	23.0
	C _{δ2}	21.9	21.7	21.9	21.9	21.8	21.9
	<i>N</i> -Me	40.0	40.0	40.0	40.3	39.8	40.0
<i>allo</i> -Ileu	C _α	56.6		56.5	56.4		56.6
	C _β	36.7		37.2	37.0		37.0
	C _{γ1}	27.3		27.3	27.2		27.3
	C _{γ2}	14.6		14.6	14.6		14.6
	C _δ	11.7		11.7	11.7		11.7
Val	C _α		58.1			58.1	
	C _β		30.6			30.5	
	C _{γ1}		20.2			20.2	
	C _{γ2}		17.1			17.2	
Ser	C _α	58.0	58.4	58.8	58.3	58.5	58.5
	C _β	61.4	61.0	61.2	61.2	61.1	61.3
<i>allo</i> -Thr	C _α	59.1	59.1	59.4	59.1	59.0	59.2
	C _β	66.9	66.5	66.8	66.7	66.8	66.8
	C _γ	18.7	18.1	18.5	18.5	18.5	18.5
Gly	C _α	40.6	40.5	40.4	40.4	40.4	40.5
Fatty acid	C-2	41.4	41.7	41.7	41.5	41.5	41.6
	C-3	76.9	76.5	76.6	76.5	76.5	76.7
	C-4	31.2	31.6	31.6	31.4	31.5	31.5
	C-5	25.3	25.2	25.3	25.2	25.2	25.3
	C-6	22.6	29.2	29.2	29.0	29.5	29.6
	C-7	13.9	31.6	31.6	29.5	29.3	29.4
	C-8		22.6	22.6	31.8	29.2	29.3
	C-9		14.0	14.0	22.6	31.8	31.8
	C-10				14.1	22.6	22.7
	C-11					14.1	14.1
	C-2-Me	15.0	15.0	15.0	15.0	15.0	15.0
C=O		169.0	168.6	168.4	168.4	168.5	168.1
		170.3	169.8	169.8	169.7	169.8	169.4
		171.1	171.6	171.1	170.2	170.9	170.9
		173.3	173.4	173.4	173.2	173.0	173.2
		174.9	174.6	175.0	174.8	174.1	174.8
		177.1	177.0	177.1	176.9	176.1	176.9

were made by conventional methods and PRFT experiments. α -Carbon peaks of amino acids were broader ($W1/2 \sim 60$ Hz), than those of the other peaks and were relatively temperature independent. However, in methanol- d_4 or in case of diacetate, these carbons showed sharp signals ($W1/2 \sim 15$ Hz), suggesting the conformational isomerism involving hydrogen bonding.


The Structures of the Four Minor Components

Acid hydrolysis of each component liberated five amino acids and one fatty acid. Those are summarized in Table 3. These degradation products were identified by comparison with authentic samples by amino acid analysis, GLC and GC-MS. Configurations of amino acids were determined by optical rotation or by GLC after conversion into *N*-trifluoroacetyl-L-prolyl-peptide methyl ester of *N*-trifluoroacetyl-L-prolyl-*O*-TMS-peptide methyl ester^{4,5}). Conventional hydrolysis with HCl gave only racemized *N*-methyl-leucine, but hydrolysis with methanesulfonic acid⁶) gave optically active one, though partially racemized. Its L-configuration was determined by optical rotation.

Structures of fatty acids were deduced by NMR and MS analysis and confirmed by chemical synthesis *via* the REFORMATSKY reaction according to BELLARSOUED⁷). Relative configuration of hydroxy fatty acids were considered to be *threo*, because $J_{2,3}$ in $R-\overset{3}{\text{C}}\text{H}-\overset{2}{\text{C}}\text{H}-\text{COOH}$ was 7.3 Hz. CANCELL *et al.* studied in detail the stereochemical outcome of the REFORMATSKY reaction, and reported that $J_{2,3}^{threo}$ of 3-hydroxy-2-methyl-phenyl-carboxylic acid was 8.6 Hz, while that of *erythro* isomer, 4.7 Hz. Indeed the synthetic mixture showed two $J_{2,3}$ values, 5 Hz and 7 Hz which could be assigned to *erythro* and *threo* respectively. The hydroxy fatty acid from $A_2 \sim A_4$ as well as A_1 and A_5 all showed $J_{2,3}$ of 7.3 Hz corresponding to a *threo* isomer. The amino acid sequence was determined by mass spectrometry of the permethylated open chain derivatives and the corresponding perdeuteromethylated analogues, as shown in Table 4. The site of lactone ring formation was considered to be identical with that in A_1 from the similarity of CMR.

Table 3. Amino acid and fatty acid constituents of SF-1902 minor components.

Components	Fatty acid* n	Amino acid					
		L-MeLeu	L- <i>allo</i> -Ileu	L-Val	L-Ser	L- <i>allo</i> -Thr	Gly
A_2	3	+	+	-	+	+	+
A_3	5	+	-	+	+	+	+
A_1 =globomycin	5	+	+	-	+	+	+
A_{4a}	6	+	+	-	+	+	+
A_{4b}	7	+	-	+	+	+	+
A_5	7	+	+	-	+	+	+

Table 4. Mass spectra of permethylated (perdeuteromethylated) seco-acids of SF-1902 components (*m/z*).

	Acyl-MeLeu	Me- <i>allo</i> -Ile (Val)	Me-Ser (OMe)	Me- <i>allo</i> -Thr (OMe)	Me-Gly (OMe)
A_2	284 (287)	411 (417)	526 (538)	655 (673)	757 (781)
A_3	312	425	540	669	771
A_1	312 (315)	439 (445)	554 (566)	683 (701)	785 (809)
A_{4a}	326 (329)	453 (459)	568 (580)	697 (715)	799 (823)
A_{4b}	340	453	568	697	799
A_5	340 (343)	467 (473)	582 (594)	711 (729)	813 (837)

These results lead to the structures shown in Fig. 1 for the minor components of SF-1902. Thus, A₂ shared five amino acids in common with A₁, but the fatty acid alkyl chain was shorter than that of A₁ by two methylenes. A₃ shared four amino acids in common with A₁ and *allo*-isoleucine was replaced by valine. The fatty acid in A₃ was identical with that in A₁. A_{4a} shared five amino acids in common with A₁, but the fatty acid contained one more carbon than that of A₁. A_{4b} shared five amino acids in common with A₃, but the fatty acid contained two more carbons than that of A₁.

Biological Properties

Antibacterial spectra of A₂~A_{4b} were compared with those of A₁ and A₅. They were active against Gram-negative bacteria, but not against Gram-positive bacteria. Of particular interest was that the antibacterial activity is quite sensitive to the length of alkyl side chain, either in a fatty acid or in an amino acid, as shown in Table 5. Replacement of valine with *allo*-isoleucine, resulting in single carbon increment, exerted 2 to 4 fold decrease in MIC value. As seen between globomycin (A₁) and A_{4a} or between A_{4a} and A₅, single carbon increase in a fatty acid side chain resulted in also 2 to 4 fold activity enhancement. SF-1902 A₅ which had the longest side chain showed the highest antibacterial activity. A₂, with the shortest side chain showed the weakest activity, though it still exhibited considerable activity against *Salmonella interitidis* and *Shigella flexneri*. Globomycin (SF-1902 A₁) was intermediate in both

Table 5. Antimicrobial spectrum of SF-1902 minor components.

Organisms	MIC (mcg/ml)					
	A ₂	A ₃	A ₁ =Glo- bomycin	A _{4a}	A _{4b}	A ₅
<i>Staphylococcus aureus</i> 209P JC-1	>100	>100	>100	>100	>100	>100
<i>Staphylococcus aureus</i> Smith	>100	>100	>100	100	100	100
<i>Bacillus anthracis</i> No. 119	>100	>100	>100	100	100	100
<i>Escherichia coli</i> NIHJ JC-2	50	25	6.25	3.13	3.13	1.56
<i>Escherichia coli</i> No. 29	50	25	12.5	3.13	6.25	1.56
<i>Escherichia coli</i> W3630 RGN-823	25	6.25	3.13	1.56	3.13	0.78
<i>Escherichia coli</i> K-12 IAM 1264	50	12.5	6.25	3.13	6.25	1.56
<i>Escherichia coli</i> A-0014	12.5	6.25	3.13	1.56	3.13	0.78
<i>Citrobacter freundii</i> GN 346	100	50	25	12.5	25	6.25
<i>Salmonella typhimurium</i> O-901-W	25	50	12.5	3.13	6.25	3.13
<i>Salmonella paratyphi</i> A	100	50	25	6.25	6.25	3.13
<i>Salmonella enteritidis</i> No. 11	1.56	0.78	0.78	0.39	0.10	0.10
<i>Shigella flexneri</i> 2a	3.13	1.56	0.78	0.39	0.39	0.10
<i>Shigella sonnei</i> EW33 Type 1	12.5	6.25	3.13	1.56	1.56	0.78
<i>Klebsiella pneumoniae</i> PCI-602	>100	50	25	6.25	12.5	1.56
<i>Klebsiella pneumoniae</i> F-0004	6.25	3.13	1.56	0.39	0.78	0.10
<i>Proteus vulgaris</i> OX-19	>100	>100	>100	100	100	100
<i>Proteus rettgeri</i> J-0026	>100	>100	>100	25	25	6.25
<i>Serratia marcescens</i> No. 1	>100	>100	>100	50	50	25
<i>Serratia marcescens</i> MB-3848	>100	>100	>100	100	100	50
<i>Pseudomonas aeruginosa</i> MB-3829	>100	100	50	50	25	12.5
<i>Vibrio cholerae</i> var. <i>eltor</i> Inaba #930	25	6.25	3.13	0.78	1.56	0.78
<i>Vibrio cholerae</i> var. <i>eltor</i> Ogawa NIH-41	25	6.25	6.25	0.78	1.56	0.39
<i>Yersinia enterocolitica</i> O: 3 (2H20)	>100	25	25	25	25	6.25
<i>Yersinia enterocolitica</i> O: 5 (334)	>100	100	100	100	50	25

the side chain length and activity.

Since acetylation of hydroxyl groups in serine and *allo*-threonine diminished activity, the two hydroxyl groups seem to be essential for antibacterial activity. However, the diphosphate of globomycin in which hydroxyl groups of serine and *allo*-threonine were phosphorylated retained antibacterial activity to some selected bacteria (MIC; 12.5 mcg/ml against *Escherichia coli* W3630 RGN 823, and 25 mcg/ml against *Shigella sonnei* EW 33 Type I). On the other hand mono-phosphate (Ser) showed no antibacterial activity. Open chain compounds (seco-acids) also completely lost bioactivity. These results indicate that the presence of long side chain of lipophilic nature and a cyclic structure with inner hydrophilic hole are essential for the antibacterial activity of globomycin analogues.

INUKAI *et al.* reported that globomycin inhibited the prolipoprotein processing enzyme of Gram-negative bacteria⁸⁾. Since the new analogues of globomycin probably possess the same mechanism of action, these new antibiotics, especially A₅ will be suitable tools in the study of bacterial lipoprotein synthesis in outer membrane.

Intraperitoneal administration of each component at a dose of 180 mg/kg caused no death of mice.

Experimentals

HPLC Analysis

HPLC analysis of SF-1902 minor components was carried out on Nucleosil 5C₁₈ (4.6 mm × 150 mm), μ Bondapak C₁₈ (4.6 mm × 250 mm) or Develosil ODS-7 (Nomura Kagaku, Osaka) (4.6 mm × 250 mm) developed with 60~70% aqueous acetonitrile. Components were detected with a UV detector at 220 nm.

Separation of Four Products

a) Preliminary separation: Crude extract (16 g) was applied to silica gel column (Wako-gel C-300, 40 mm × 250 mm) and developed with a mixture of chloroform - methanol (40: 1~20: 1) (flow rate: 6~10 ml/minute, 10~25 kg/cm²). Biologically active effluents were divided roughly into three fractions after HPLC analysis. Most of A₄ was distributed in the first fraction (1.7 g; A_{4a}+A_{4b}: 3%, A₅: 36%, globomycin: 42%). A₂ and A₃ were concentrated in the third fraction (4.5 g; A₂: 5%, A₃: 26%, globomycin: 45%). The second fraction gave crystalline globomycin containing less than 10% of minors. After concentration, followed by addition of acetonitrile, all three fractions afforded crystalline mixture of SF-1902 components. Separation of minor components by fractional crystallization failed.

b) Complete separation: 1) A sample of the first fraction (1.7 g) was chromatographed over LiChroprep RP-8 (25~40 μ , E. Merck) column (40 mm × 250 mm) and developed with 55% aqueous acetonitrile (4.5 ml/minute; 20 kg/cm²). Pure components except A_{4a} and A_{4b} were obtained by this methods. Separation of A_{4a} from A_{4b} was still incomplete under this condition. A₄ mixture sample (51 mg) was chromatographed over Nucleosil 5C₁₈ (10 mm × 250 mm) and eluted with 70% aqueous acetonitrile (2.0 ml/minute; 120 kg/cm²) to carry out the final separation. Complete separation of A_{4a} from A_{4b} needed repeated chromatography over the same column.

2) A sample of the third fraction (4.5 g) was chromatographed over Nucleosil 5C₁₈ (10 mm × 250 mm) and developed with 60% aqueous acetonitrile (1.3~1.7 ml/minute; 55~78 kg/cm²), in order to obtain pure samples of A₂ and A₃. Each component was finally purified by recrystallization from 60% aqueous acetonitrile.

Isolation of Optically Active *N*-Methyleucine

A sample of a minor component (300 mg) was hydrolyzed in 4 M methanesulfonic acid (30 ml) containing 0.2% tryptamine at 110°C for 20 hours. After neutralization by aqueous NaOH, the hydrolysate was passed through a small column of Dowex 50W- \times 2 (H⁺), which was washed with water followed by elution with 0.5 N NH₄OH. After concentration, the eluate was subjected to chromatography

on cellulose (70% isopropanol) and then Dowex 50W- $\times 2$ (pyridine - formic acid, pH 3.1; 0.1 M) to give a pure sample of *N*-methylleucine (25 mg): $[\alpha]_D^{20} + 10^\circ$ (*c* 1.1, 5 N HCl). (Ref. $[\alpha]_D^{15} + 31.3^\circ$ (*c* 0.9, 5 N HCl)¹⁹).

Permethylation of Seco-acid

To a solution of seco-acid of a minor component (3~5 mg) in freshly distilled dry DMSO (2 ml) was added methylsulfinyl carbanion in DMSO (0.5 ml; prepared from NaH; 50%, 200 mg and DMSO; 2 ml) under nitrogen. After 15 minutes at room temperature, 200 μ l of CH₃I was carefully added and stirred for 2 hours. After usual work-up, the product was subjected to MS-analysis.

Preparation of Mono- and Di-phosphates

Globomycin (SF-1902 A₁) (2.0 g) was reacted with diphenylphosphorochloridate (2.43 g) in dry pyridine (45 ml) at -20°C for 2 hours. The reaction product, after ethyl acetate extraction and concentration, was immediately subjected to catalytic hydrogenolysis for 2.5 hours. PtO₂ (500 mg) was used in 70% aqueous ethanol (200 ml) containing acetic acid (0.5 ml). After usual work-up, the product was subjected to silica gel column chromatography (CHCl₃ - MeOH=10:1~5:1) to give diphosphate (530 mg): glass, m.p. 147~159°C, $[\alpha]_D^{20} + 12^\circ$ (*c* 1, CHCl₃) and monophosphate (220 mg): glass, m.p. 139~142°C, $[\alpha]_D^{20} + 26^\circ$ (*c* 1, CHCl₃).

In the CMR spectrum of monophosphate, β -C of serine underwent low field shift of 3.4 ppm ($J_{\text{COP}} = 3.4$ Hz) (in CD₃OD - CDCl₃). Neutralization with 1 N NaOH gave the respective sodium salts; diphosphate sodium salt: m.p. 140~143°C, $[\alpha]_D^{20} + 7.3^\circ$ (*c* 1, H₂O), ³¹P NMR (in D₂O) -3.71 and -4.65 ppm from external Pi, monophosphate sodium salt: m.p. 125~127°C, $[\alpha]_D^{20} + 14^\circ$ (*c* 1, H₂O), ³¹P NMR (in D₂O) -4.18 ppm from external Pi.

Acknowledgements

We wish to thank Mrs. S. FURUTA for MS measurements, members of Pharmaceutical Development Laboratories for large scale production of SF-1902 A group and Mr. K. MIYAUCHI for antibacterial data.

References

- 1) NAKAJIMA, M.; M. INUKAI, T. HANEISHI, A. TERAHARA, M. ARAI, T. KINOSHITA & C. TAMURA: Globomycin, a new peptide antibiotic with spheroplast-forming activity. III. Structural determination of globomycin. *J. Antibiotics* 31: 426~432, 1978
- 2) OMOTO, S.; H. SUZUKI & S. INOUE: Isolation and structure of SF-1902 A₅, a new globomycin analogue. *J. Antibiotics* 32: 83~86, 1979
- 3) SHOMURA, T.; S. OMOTO, M. KOJIMA, H. WATANABE, S. INOUE & T. NIIDA: Studies on a new antibiotic SF-1902. I. Producing microorganism, isolation and characterization. *Sci. Reports of Meiji Seika Kaisha* 17: 7~11, 1976
- 4) HALPERN, B. & J. W. WESTLEY: High sensitivity optical resolution of D, L amino acids by gas chromatography. *Biochem. Biophys. Res. Comm.* 19: 361~363, 1965
- 5) HALPERN, B. & J. W. WESTLEY: High sensitivity optical resolution of poly-functional amino acids by gas liquid chromatography. *Tetrahed. Lett.* 1966: 2283~2286, 1966
- 6) SIMPSON, R. J.; M. R. NEUBERGER & T.-Y. LIU: Complete amino acid analysis of proteins from a single hydrolyzate. *J. Biol. Chem.* 251: 1936~1940, 1976
- 7) BELLARSOUED, M.; R. COUFFIGNAL & M. GAUDEMAR: The direct synthesis of β -hydroxy acids *via* the REFORMATSKY reaction. *J. Organometal. Chem.* 61: 9~18, 1973
- 8) INUKAI, M.; M. TAKEUCHI, K. SHIMIZU & M. ARAI: Mechanism of action of globomycin. *J. Antibiotics* 31: 1203~1205, 1978
- 9) PLATTNER, P. A. & U. F. NAGER: Wilting agents and antibiotics. X. The structure of enniatin A. *Helv. Chim. Acta* 31: 2192~2203, 1948